4D Molecular Therapeutics Inc (FDMT) financials
4D Molecular Therapeutics revenue and earnings by year
4D Molecular Therapeutics's revenue was $85.2 million in the fiscal year to December 31, 2025, up 230194.6% from the year before. Net income was -$140 million, -164.4% of revenue. Since the fiscal year to December 31, 2018, revenue has grown 29.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 8 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 85 | 0 | 21 | 3 | 18 | 14 | 7 | 14 |
| Revenue growth | 230194.6% | -99.8% | 562.3% | -82.7% | 32.5% | 94.8% | -50.6% | — |
| Operating income | -160 | -188 | -113 | -110 | -71 | -57 | -51 | -10 |
| Operating margin | -187.2% | -507678.4% | -544.6% | -3516.5% | -395.5% | -416.3% | -726.7% | -73.6% |
| Net income | -140 | -161 | -101 | -107 | -71 | -57 | -49 | -10 |
| Net margin | -164.4% | -434778.4% | -486.6% | -3435.4% | -395.4% | -416.5% | -705.8% | -67.6% |
| Diluted EPS | -$2.42 | -$2.98 | -$2.58 | -$3.32 | -$2.56 | -$8.82 | — | — |
| Free cash flow | -110 | -138 | -79 | -98 | -78 | -52 | -40 | -17 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open FDMT in Markets.
See also: FDMT returns
No forecast, no recommendation. This page describes 4D Molecular Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.